Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	June 30, 2020	High Trail	Asset Purchase Agreement	Common Stock	Common Stock June 30, 2020	Common Stock March 12, 2020	Common Stock High Trail	Common Stock Asset Purchase Agreement	Additional Paid-in Capital	Additional Paid-in Capital High Trail	Additional Paid-in Capital Asset Purchase Agreement	Retained Earnings	AOCI Attributable to Parent
Beginning balance at Dec. 31, 2020	$ 23,382				$ 3					$ 216,305			$ (192,935)	$ 9
Beginning balance, shares at Dec. 31, 2020					27,074,791
Net loss	(229,415)												(229,415)
Issuance of common stock upon exercise of stock option grants	8,749									8,749
Issuance of common stock upon exercise of stock option grants, shares					1,011,422
Issuance of common stock related to exercise of warrants	40,284									40,284
Issuance of common stock related to exercise of warrants, shares					2,926,508
Issuance of common stock in connection with acquisition of Healing Solutions assets	39,454									39,454
Issuance of common stock in connection with acquisition of Healing Solutions assets, shares					1,387,759
Issuance of restricted stock awards	4,412									4,412
Issuance of restricted stock awards, shares					254,104
Issuance of warrants to High Trail	39,016									39,016
Issuance of common stock	36,735		$ 129,620	$ 11,075				$ 2		36,735	$ 129,618	$ 11,075
Issuance of common stock, shares					2,666,667			12,284,161	704,548
Reclassification of warrants to equity	97,088									97,088
Reclassification of warrants to liability	(21,260)									(21,260)
Fair value of warrant modification on extinguishment	17,399									17,399
Issuance of restricted common stock, shares					2,020,697
Forfeiture of restricted common stock, shares					(280,997)
Exercise of stock options	8,749									8,749
Exercise of stock options, shares					1,011,422
Stock-based compensation expense	16,421									16,421
Other comprehensive loss	(305)													(305)
Ending balance at Sep. 30, 2021	212,655				$ 5					635,296			(422,350)	(296)
Ending balance, shares at Sep. 30, 2021					50,049,660
Issuance of warrants in connection with offering	(97,088)									(97,088)
Beginning balance at Jun. 30, 2021	175,777				$ 3					487,605			(311,794)	37
Beginning balance, shares at Jun. 30, 2021					35,734,767
Net loss	(110,556)												(110,556)
Issuance of common stock upon exercise of stock option grants	17,399									17,399
Issuance of common stock upon exercise of stock option grants, shares					32,927
Issuance of common stock related to exercise of warrants, shares					1,879,368
Issuance of common stock			$ 125,564					$ 2			$ 125,562
Issuance of common stock, shares								12,154,161
Reclassification of warrants to equity	17,065									17,065
Reclassification of warrants to liability	(21,260)									(21,260)
Issuance of RSU issued to consultant	1,043									1,043
Issuance of RSU issued to consultant, shares					145,408
Issuance of restricted common stock, shares					125,055
Forfeiture of restricted common stock, shares					22,026
Exercise of stock options	17,399									17,399
Exercise of stock options, shares					32,927
Stock-based compensation expense	7,882									7,882
Other comprehensive loss	(259)													(259)
Ending balance at Sep. 30, 2021	212,655				$ 5					635,296			(422,350)	(296)
Ending balance, shares at Sep. 30, 2021					50,049,660
Issuance of warrants in connection with offering	(17,065)									(17,065)
Beginning balance at Dec. 31, 2021	224,228				$ 5					653,650			(428,959)	(468)
Beginning balance, shares at Dec. 31, 2021					55,090,237
Net loss	(175,987)												(175,987)
Issuance of common stock	43									43
Issuance of common stock, shares					23,362
Issuance of common stock	27,007				$ 1					27,006
Issuance of common stock, shares					7,003,332
Reclassification of warrants to equity	18,982									18,982
Issuance of restricted common stock, shares		$ 1				$ 1
Issuance of restricted common stock, shares						4,350,642
Forfeiture of restricted common stock, shares							(233,561)
Exercise of prefunded warrants	15,039									15,039
Exercise of prefunded warrants, shares					3,013,850
Issuance of common stock for settlement of seller note	767									767
Issuance of common stock for settlement of seller note, shares					292,887
Loss on initial issuance of equity	18,669									18,669
Issuance of warrants to contractors	1,137									1,137
Stock-based compensation expense	8,446									8,446
Other comprehensive loss	(1,087)													(1,087)
Ending balance at Sep. 30, 2022	99,281				$ 7					705,775			(604,946)	(1,555)
Ending balance, shares at Sep. 30, 2022					69,540,749
Issuance of warrants in connection with offering	(18,982)									(18,982)
Beginning balance at Jun. 30, 2022	200,848				$ 7					689,955			(488,044)	(1,070)
Beginning balance, shares at Jun. 30, 2022					69,219,384
Net loss	(116,902)												(116,902)
Issuance of common stock	43									43
Issuance of common stock, shares					23,362
Issuance of restricted common stock, shares						329,968
Forfeiture of restricted common stock, shares						(31,965)
Loss on initial issuance of equity	12,834									12,834
Stock-based compensation expense	2,943									2,943
Other comprehensive loss	(485)													(485)
Ending balance at Sep. 30, 2022	$ 99,281				$ 7					$ 705,775			$ (604,946)	$ (1,555)
Ending balance, shares at Sep. 30, 2022					69,540,749